skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 3,499  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: resource type: Newsletter Articles remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Corcept: Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients with Hypercortisolism
Material Type:
Newsletter Article
Add to My Research

Corcept: Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients with Hypercortisolism

Manufacturing Close - Up, 2024

Copyright Close-Up Media, Inc. Jun 4, 2024

Digital Resources/Online E-Resources

2
Corcept Therapeutics (CORT: $32.87) up 8.9% in 2 days, hits 263-day high; +$2.70 [8.9%]
Material Type:
Newsletter Article
Add to My Research

Corcept Therapeutics (CORT: $32.87) up 8.9% in 2 days, hits 263-day high; +$2.70 [8.9%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 4, 2024

Digital Resources/Online E-Resources

3
Corcept Therapeutics (CORT: $31.30) up 3.7% after an upgrade this week; +$1.13 [3.7%]
Material Type:
Newsletter Article
Add to My Research

Corcept Therapeutics (CORT: $31.30) up 3.7% after an upgrade this week; +$1.13 [3.7%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 3, 2024

Digital Resources/Online E-Resources

4
Weekly: Corcept Therapeutics (CORT: $30.13) in top 1% performers of NASDAQ market in past week; +$2.61 [9.5%] Vol Index 1.7 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Weekly: Corcept Therapeutics (CORT: $30.13) in top 1% performers of NASDAQ market in past week; +$2.61 [9.5%] Vol Index 1.7 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 3, 2024

Digital Resources/Online E-Resources

5
Monthly: Corcept Therapeutics (CORT: $30.17) adds $727 million in MCap in May, leads Medical/Drugs sector gains
Material Type:
Newsletter Article
Add to My Research

Monthly: Corcept Therapeutics (CORT: $30.17) adds $727 million in MCap in May, leads Medical/Drugs sector gains

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 3, 2024

Digital Resources/Online E-Resources

6
Monthly: Achieve Life Sciences (ACHV: $5.22) rises 19% on high volatility in May 2024
Material Type:
Newsletter Article
Add to My Research

Monthly: Achieve Life Sciences (ACHV: $5.22) rises 19% on high volatility in May 2024

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 3, 2024

Digital Resources/Online E-Resources

7
Press Release: KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
Material Type:
Newsletter Article
Add to My Research

Press Release: KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. Jun 1, 2024

Digital Resources/Online E-Resources

8
Achieve Life Sciences (ACHV: $5.22) accelerates decline, down 2.2% in 2 days; -12c [2.2%] Vol Index 1.8 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $5.22) accelerates decline, down 2.2% in 2 days; -12c [2.2%] Vol Index 1.8 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 1, 2024

Digital Resources/Online E-Resources

9
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
Material Type:
Newsletter Article
Add to My Research

KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer

Business Wire, 2024

Copyright Business Wire 2024

Digital Resources/Online E-Resources

10
Achieve Life Sciences (ACHV: $5.29) decreases, 2 days' volume in a day; -5c [0.9%] Vol Index 1.7 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $5.29) decreases, 2 days' volume in a day; -5c [0.9%] Vol Index 1.7 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 31, 2024

Digital Resources/Online E-Resources

11
Corcept Therapeutics (CORT: $30.13) offers earnings yield of 3.3
Material Type:
Newsletter Article
Add to My Research

Corcept Therapeutics (CORT: $30.13) offers earnings yield of 3.3

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 31, 2024

Digital Resources/Online E-Resources

12
Corcept Therapeutics top gainer in Roanoke Asset Management jumps 23.9% in 63 days; -$1.08 [3.5%] Vol Index 1.2 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Corcept Therapeutics top gainer in Roanoke Asset Management jumps 23.9% in 63 days; -$1.08 [3.5%] Vol Index 1.2 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 31, 2024

Digital Resources/Online E-Resources

13
Corcept Therapeutics (CORT: $31.21) loses $33 million (1.0%) in MCap, steepest heavyweight fall in Medical/Drugs sector; -32c [1.0%]
Material Type:
Newsletter Article
Add to My Research

Corcept Therapeutics (CORT: $31.21) loses $33 million (1.0%) in MCap, steepest heavyweight fall in Medical/Drugs sector; -32c [1.0%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 30, 2024

Digital Resources/Online E-Resources

14
Clinical Trial: Prevalence of Birth Before Arrival and Associated Factors Among Postpartum Women in Southern Ethiopia
Material Type:
Newsletter Article
Add to My Research

Clinical Trial: Prevalence of Birth Before Arrival and Associated Factors Among Postpartum Women in Southern Ethiopia

US Fed News Service, Including US State News, 2024

Copyright HT Digital Streams Limited May 30, 2024

Digital Resources/Online E-Resources

15
Achieve Life Sciences top gainer in Propel Bio Management jumps 17.9% in 61 days, hits 173-day high; -3c [0.6%] Vol Index 1.6 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences top gainer in Propel Bio Management jumps 17.9% in 61 days, hits 173-day high; -3c [0.6%] Vol Index 1.6 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 30, 2024

Digital Resources/Online E-Resources

16
Corcept Therapeutics Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushings Syndrome)
Material Type:
Newsletter Article
Add to My Research

Corcept Therapeutics Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushings Syndrome)

News Bites - Healthcare & Equipment, 2024

Copyright News Bites Pty Ltd May 29, 2024

Digital Resources/Online E-Resources

17
Achieve Life Sciences (ACHV: $5.36) falls 3.9% from 14-day high; -5c [0.9%] Vol Index 2.0 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

Achieve Life Sciences (ACHV: $5.36) falls 3.9% from 14-day high; -5c [0.9%] Vol Index 2.0 [1 is avg]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 29, 2024

Digital Resources/Online E-Resources

18
Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Phase 3 Study
Material Type:
Newsletter Article
Add to My Research

Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Phase 3 Study

PR Newswire, 2024

Copyright PR Newswire Association LLC May 29, 2024

Digital Resources/Online E-Resources

19
Press Release: Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Phase 3 Study
Material Type:
Newsletter Article
Add to My Research

Press Release: Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Phase 3 Study

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. May 29, 2024

Digital Resources/Online E-Resources

20
Corcept Therapeutics (CORT: $31.53) down 0.3% after a second upgrade; -8c [0.3%]
Material Type:
Newsletter Article
Add to My Research

Corcept Therapeutics (CORT: $31.53) down 0.3% after a second upgrade; -8c [0.3%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 29, 2024

Digital Resources/Online E-Resources

Results 1 - 20 of 3,499  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2001  (22)
  2. 2001 To 2006  (122)
  3. 2007 To 2012  (421)
  4. 2013 To 2019  (854)
  5. After 2019  (2,081)
  6. More options open sub menu

Language 

  1. English  (3,464)
  2. German  (16)
  3. Spanish  (8)
  4. Portuguese  (5)
  5. Italian  (3)
  6. French  (3)
  7. More options open sub menu

Searching Remote Databases, Please Wait